BASILICO, Annacristina

BASILICO, Annacristina  

ONCOLOGIA  

Mostra records
Risultati 1 - 15 di 15 (tempo di esecuzione: 0.015 secondi).
Titolo Data di pubblicazione Autore(i) File
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met 2008 Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P
"Active" cancer immunotherapy by anti-Met antibody gene transfer 2008 Vigna E; Pacchiana G; Mazzone M; Chiriaco C; Fontani L; Basilico C; Pennacchietti S; Comoglio PM
An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. 2002 MICHIELI P; CAVASSA S; BASILICO C; DE LUCA A; MAZZONE M; ASTI C; CHIUSAROLI R; GUGLIELMI M; BOSSU' P; COLOTTA F; CASELLI G; PM COMOGLIO
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice 2004 MAZZONE M; BASILICO C; CAVASSA S; PENNACCHIETTI S; RISIO M; NALDINI L; PM COMOGLIO; MICHIELI P
Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor 2021 Desole C.; Gallo S.; Vitacolonna A.; Vigna E.; Basilico C.; Montarolo F.; Zuppini F.; Casanova E.; Miggiano R.; Ferraris D.M.; Bertolotto A.; Comoglio P.M.; Crepaldi T.
Hgf/met axis induces tumor secretion of tenascin-c and promotes stromal rewiring in pancreatic cancer 2021 Modica C.; Olivero M.; Zuppini F.; Milan M.; Basilico C.; Vigna E.
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers 2022 Martinelli I.; Modica C.; Chiriaco C.; Basilico C.; Hughes J.M.; Corso S.; Giordano S.; Comoglio P.M.; Vigna E.
Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis 2008 Cassano M; Biressi S; Finan A; Benedetti L; Omes C; Boratto R; Martin F; Allegretti M; Broccoli V; Cusella De Angelis G; Comoglio PM; Basilico C; Torrente Y; Michieli P; Cossu G; Sampaolesi M
MET/HGF co-targeting in pancreatic cancer: A tool to provide insight into the tumor/stroma crosstalk 2018 Modica C.; Tortarolo D.; Comoglio P.M.; Basilico C.; Vigna E.
Molecular engineering strategies tailoring the apoptotic response to a met therapeutic antibody 2020 Modica C.; Gallo S.; Chiriaco C.; Spilinga M.; Comoglio P.M.; Crepaldi T.; Basilico C.; Vigna E.
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. 1999 P. MICHIELI; C. BASILICO; S. PENNACCHIETTI; A. MAFFE'; L. TAMAGNONE; S. GIORDANO; A. BARDELLI; P.M. COMOGLIO
A receptor-antibody hybrid hampering MET-driven metastatic spread 2021 Modica C.; Basilico C.; Chiriaco C.; Borrelli N.; Comoglio P.M.; Vigna E.
Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy 2018 Basilico C.; Modica C.; Maione F.; Vigna E.; Comoglio P.M.
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor 2004 MICHIELI P; MAZZONE M; BASILICO C; CAVASSA S; SOTTILE A; NALDINI L; P. COMOGLIO
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth 1998 BARDELLI A.; LONGATI P.; GRAMAGLIA D.; BASILICO C.; TAMAGNONE L.; GIORDANO S; BALLINARI D.; MICHIELI P.; P. COMOGLIO